



Conflict Minerals Statement

Introduction

AstraZeneca is committed to ensuring that it conducts its business worldwide with respect for human rights as outlined in our [Human Rights Statement](#). This includes conducting necessary due diligence to determine whether we source any conflict minerals (tantalum, tin, tungsten and gold) in any of the products that we manufacture or contract to manufacture, which would subject us to the necessary related reporting requirements. If a product does contain these minerals, AstraZeneca is committed to performing extended due diligence to determine chain of custody or traceability documentation.

Background

In 2012, the U.S. Securities and Exchange Commission (SEC) issued rules implementing the “conflict minerals” disclosure requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank). Under these rules, organisations that use conflict minerals are required to report annually to the SEC on any use of conflict minerals originating in the Democratic Republic of Congo (DRC) or any of the DRC’s adjoining countries in products manufactured by the Company.

Underlying the Dodd-Frank disclosure requirements is a concern that conflict minerals originating in the DRC or adjoining countries may be mined and sold by armed groups to finance civil violence. These minerals can ultimately make their way into products used by businesses around the world.



Our Approach to Conflict Minerals Monitoring

While these minerals have not historically been used in the medicines we manufacture, these items are potentially used in the manufacture of medical devices. As such, AstraZeneca continually monitors all new product development for these minerals and acts to mitigate any related human rights risks utilising the [Organisation for Economic Co-operation and Development's \(OECD\) Due Diligence Guidance for Responsible Mineral Supply Chains](#), and, where appropriate, their [five-step framework](#).

If a product is deemed to use these minerals, we will take measured actions to ensure compliance by:

- conducting a reasonable country of origin inquiry with our global supply base as part of our conflict minerals due diligence process;
- collecting and evaluating all supplier responses to the Responsible Minerals Initiative (RMI) Conflict Minerals Reporting Template (CMRT); and
- publicly reporting a summary of our findings to both the SEC and our website.

AstraZeneca requires that all direct suppliers support the necessary extended supply chain due diligence to identify the source of their minerals and ensure they are not inadvertently funding conflict and benefiting armed groups.

AstraZeneca does not ban sourcing from conflict-affected or high-risk areas of the world as we recognise these minerals are vitally important to the economies of the region. We encourage our suppliers to continue to source responsibly from these areas.

Supply chains are complex, and only together can we maintain and enhance the trust of our customers and stakeholders

It is critically important to us that the Third Parties we work with share our Values and ensure that any work on our behalf upholds our ethical standards. As such, we have also embedded conflict minerals compliance into our onboarding and contracting process by:

- communicating our [Expectations of Third Parties](#) that requires our suppliers to comply with any applicable laws and regulations regarding conflict minerals and assist us in meeting our obligations under law and regulations; and
- including a contractual clause related to conflict minerals in new or renewed supplier contracts as part of our standard Terms and Conditions.

We will immediately suspend or discontinue engagement with any suppliers where we identify a reasonable risk that they are sourcing from, or linked to, any party committing serious human rights abuses.

AstraZeneca continues to make every effort possible to improve livelihoods for those people around the world that ultimately deliver our purpose: to push the boundaries of science to deliver life-changing medicines.